JP2002524410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002524410A5 JP2002524410A5 JP2000568476A JP2000568476A JP2002524410A5 JP 2002524410 A5 JP2002524410 A5 JP 2002524410A5 JP 2000568476 A JP2000568476 A JP 2000568476A JP 2000568476 A JP2000568476 A JP 2000568476A JP 2002524410 A5 JP2002524410 A5 JP 2002524410A5
- Authority
- JP
- Japan
- Prior art keywords
- mixture
- composition
- methylcellulose
- lipase inhibitor
- starch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 34
- 229940086609 Lipase inhibitor Drugs 0.000 description 11
- 229920000609 methyl cellulose Polymers 0.000 description 11
- 239000001923 methylcellulose Substances 0.000 description 11
- 235000010980 cellulose Nutrition 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- 159000000007 calcium salts Chemical class 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- 208000034347 Faecal incontinence Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 206010041969 Steatorrhoea Diseases 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000001162 steatorrhea Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 3
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical group O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- -1 veegum Polymers 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9939998P | 1998-09-08 | 1998-09-08 | |
| US60/099,399 | 1998-09-08 | ||
| PCT/US1999/020744 WO2000013667A1 (en) | 1998-09-08 | 1999-09-08 | Lipstatin derivative-soluble fiber tablets |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002524410A JP2002524410A (ja) | 2002-08-06 |
| JP2002524410A5 true JP2002524410A5 (enExample) | 2006-11-02 |
Family
ID=22274826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000568476A Pending JP2002524410A (ja) | 1998-09-08 | 1999-09-08 | リプスタチン誘導体−可溶性繊維錠剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6607749B1 (enExample) |
| EP (1) | EP1112063A4 (enExample) |
| JP (1) | JP2002524410A (enExample) |
| AU (1) | AU745697B2 (enExample) |
| CA (1) | CA2342625A1 (enExample) |
| NZ (1) | NZ510311A (enExample) |
| WO (1) | WO2000013667A1 (enExample) |
| ZA (1) | ZA200101904B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6607749B1 (en) * | 1998-09-08 | 2003-08-19 | Smithkline Beecham Corporation | Lipstatin derivative-soluble fiber tablets |
| RU2241462C2 (ru) | 2000-07-28 | 2004-12-10 | Ф. Хоффманн-Ля Рош Аг | Новая фармацевтическая композиция |
| DE10160409A1 (de) * | 2001-12-10 | 2003-06-18 | Guenther Beisel | Verwendung von ionischen und nichtionischen Celluloseethern zur Herstellung eines gelartigen Mittels zur Verhinderung der Resorption von Fetten aus dem Magen-Darm-Trakt |
| US20040091450A1 (en) * | 2002-02-26 | 2004-05-13 | The Procter & Gamble Company | Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body |
| US20080075688A1 (en) * | 2003-10-31 | 2008-03-27 | The Procter & Gamble Company | Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body |
| EP1681050A1 (en) * | 2005-01-13 | 2006-07-19 | Strides Arcolab Limited | Dispersible sustained release pharmaceutical compositions |
| WO2006085497A1 (ja) * | 2005-02-09 | 2006-08-17 | Kissei Pharmaceutical Co., Ltd. | 口腔内崩壊錠 |
| US20070123490A1 (en) * | 2005-11-30 | 2007-05-31 | Yokoyama Wallace H | Preventing or reducing oxidative stress or oxidative cell injury |
| US20080119540A1 (en) * | 2006-11-21 | 2008-05-22 | D.N. Halgren | Method of using oral lipase inhibitors to reduce plasma ghrelin and to prevent weight regain |
| GB0618725D0 (en) * | 2006-09-23 | 2006-11-01 | Jagotec Ag | Composition containing inhibitors of gastro-intestinal lipase |
| NZ580891A (en) * | 2007-05-16 | 2012-06-29 | Buckman Labor Inc | Methods to control organic contaminants in fibers in paper making systems |
| EP2002825B1 (en) * | 2007-06-14 | 2013-05-22 | Krka | Pharmaceutical compositions comprising orlistat |
| US20100112122A1 (en) * | 2008-04-30 | 2010-05-06 | Yun-Jeong Hong | Method of preferentially reducing absorbability of saturated fatty acids |
| KR20100075260A (ko) * | 2008-12-24 | 2010-07-02 | 주식회사종근당 | 리파아제 저해제의 부작용 개선을 위한 신규한 약제학적 조성물 |
| CN102362863B (zh) * | 2011-11-21 | 2013-06-12 | 山东新时代药业有限公司 | 一种含奥利司他的制剂及其制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5438167B2 (enExample) * | 1974-04-27 | 1979-11-19 | ||
| JPS608117B2 (ja) | 1977-02-08 | 1985-02-28 | 財団法人微生物化学研究会 | 新生理活性物質エステラスチンおよびその製造法 |
| GB2023604B (en) | 1978-05-25 | 1982-07-28 | Microbial Chem Res Found | Physiologically active derivatives of esterastin and production thereof |
| US5374430A (en) * | 1986-09-18 | 1994-12-20 | London School Of Pharmacy | Pharmaceutical formulation |
| US5576306A (en) * | 1991-03-01 | 1996-11-19 | Dow Chemical Company | Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers |
| HUT70029A (en) * | 1991-08-14 | 1995-09-28 | Procter & Gamble Pharma | Novel cyclic urea derivatives and antiarrhythmic and antifibrillatory compositions containing them |
| US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
| CA2098167C (en) * | 1992-06-24 | 2006-12-19 | Dorothea Isler | Foodstuffs and feedstuffs containing a lipase inhibitor |
| TW381025B (en) | 1993-08-05 | 2000-02-01 | Hoffmann La Roche | Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor |
| US5451409A (en) * | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
| US5773031A (en) * | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
| US6004996A (en) * | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| AU8699298A (en) * | 1997-08-11 | 1999-03-01 | Alza Corporation | Prolonged release active agent dosage form adapted for gastric retention |
| AR017512A1 (es) * | 1997-08-22 | 2001-09-12 | Smithkline Beecham Corp | Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas |
| AR016827A1 (es) | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA |
| AU759388B2 (en) | 1998-08-14 | 2003-04-10 | Cheplapharm Arzneimittel Gmbh | Pharmaceutical compositions containing lipase inhibitors and chitosan |
| TR200100471T2 (tr) | 1998-08-14 | 2001-07-23 | F.Hoffmann-La Roche Ag | Lipaz inhibitörleri içeren farmasötik bileşimler |
| US6607749B1 (en) * | 1998-09-08 | 2003-08-19 | Smithkline Beecham Corporation | Lipstatin derivative-soluble fiber tablets |
| FR2795326B1 (fr) * | 1999-06-28 | 2001-08-31 | Adir | Composition pharmaceutique solide thermoformable a liberation controlee |
-
1999
- 1999-09-08 US US09/786,518 patent/US6607749B1/en not_active Expired - Fee Related
- 1999-09-08 CA CA002342625A patent/CA2342625A1/en not_active Abandoned
- 1999-09-08 NZ NZ510311A patent/NZ510311A/en not_active IP Right Cessation
- 1999-09-08 WO PCT/US1999/020744 patent/WO2000013667A1/en not_active Ceased
- 1999-09-08 JP JP2000568476A patent/JP2002524410A/ja active Pending
- 1999-09-08 AU AU58198/99A patent/AU745697B2/en not_active Ceased
- 1999-09-08 EP EP99945631A patent/EP1112063A4/en not_active Ceased
-
2001
- 2001-03-07 ZA ZA2001/01904A patent/ZA200101904B/en unknown
-
2003
- 2003-06-24 US US10/602,955 patent/US7393545B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002524410A5 (enExample) | ||
| JP2001513545A5 (enExample) | ||
| JP3276962B2 (ja) | 安定な医薬組成物 | |
| AU2001268719B2 (en) | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates | |
| EP0859603B1 (en) | Sustained release matrix for high-dose insoluble drugs | |
| CA2182004C (en) | Film coated tablet of paracetamol and domperidone | |
| FI4066821T3 (fi) | Neratinibimaleaatin tablettiformulaatioita | |
| KR20060015641A (ko) | 트립탄 및 ｎｓａｉｄ를 포함하는 조성물 | |
| KR100694550B1 (ko) | 고용량의 이반드로네이트 제형물 | |
| NZ509832A (en) | New oral formulation for 5-HT4 agonists or antagonists | |
| JPS5883618A (ja) | ニトロフラントイン投与剤 | |
| AU2004275569B2 (en) | Pharmaceutical formulation with improved stability | |
| CA2532485A1 (en) | Tablets containing ambroxol | |
| CA2361843C (en) | Swallowable tablets with high content of n-acetylcysteine | |
| JP4970452B2 (ja) | メトホルミン徐放性錠剤およびその製造方法 | |
| JP2009515956A (ja) | テルミサルタンの医薬組成物 | |
| JP2012512242A (ja) | ウデナフィル含有徐放性製剤を製造するための制御放出組成物 | |
| RU2007125122A (ru) | Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения | |
| AU2007263261B2 (en) | Galenical formulations of aliskiren and hydrochlorothiazide | |
| US20090155369A1 (en) | Pharmaceutical composition containing levodopa, entacapone and carbidopa | |
| CA2566331A1 (en) | Oral delivery system | |
| AU2002224011B2 (en) | A pharmaceutical composition for controlled release of a beta-lactam antibiotic | |
| ES2286716T3 (es) | Composicion farmaceutica de liberacion controlada y proceso para preparar la misma. | |
| CA2373962A1 (en) | Immediate release medicinal compositions for oral use | |
| EP1207857A1 (en) | Ciprofloxacin containing pharmaceutical composition and process for the preparation thereof |